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Abstract
Purpose Although biomarkers for patients with metastatic colorectal cancer exist, the benefit patients with RAS mutated 
tumors derive from established regimens is unclear.
Methods Efficacy of therapeutic strategies available for RAS mutated patients (addition of chemotherapeutic agents and/or 
anti angiogenic agents) were investigated in fourteen randomized controlled phase III trials at trial level by meta-analysing 
individual study hazard ratios and 95% confidence intervals (95% CI) for overall survival (OS) and progression free survival 
(PFS).
Results 6810 of 10,748 patients (63.3%) were available (48.5% RAS wildtype, 51.5% RAS mutated). Across all treatment 
lines, additional treatment efficacy (chemotherapy and/or anti angiogenic agents) was significantly smaller in RAS mutated 
compared to wildtype tumors for OS and PFS. In detail, patients with RAS mutated metastatic colorectal cancer derived 
significant benefit in PFS but not in OS by the addition of either chemotherapy or anti angiogenic agents to the respective 
comparator. In patients with RAS wildtype metastatic colorectal cancer, PFS and OS were improved by the addition of 
chemotherapy or anti angiogenic agent.
Conclusion The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to 
RAS wildtype metastatic colorectal cancer, especially with regard to OS.
Keywords RAS · Angiogenic · Chemotherapy · Metastatic · Colorectal cancer
Background
The RAS protein is a member of the G protein family and 
involved in signal transduction within the mitogen activated 
protein kinases (MAPK) pathway. Genetic alterations lead 
to constitutive activation of the RAS protein with a high 
oncogenic potential in metastatic colorectal cancer (mCRC) 
(Benvenuti et al. 2007; Vogelstein et al. 1988). RAS muta-
tions (MUT) are detected in about 50% of all patients (Cun-
ningham et al. 2004; Jonker et al. 2007; Sobrero et al. 2008). 
Since 2013, RAS wildtype (WT) status is required for the use 
of anti-EGFR (epidermal growth factor receptor) agents like 
cetuximab or panitumumab (Douillard et al. 2013; Heine-
mann et al. 2014).
As EGF receptor inhibition is ineffective because of 
constitutive oncogenic signalling, (Benvenuti et al. 2007) 
systemic treatment option in patients with a RAS MUT 
tumor currently include chemotherapy (fluoropyrimidines, 
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irinotecan, oxaliplatin) with or without anti angiogenic 
agents for two treatment lines, followed by later-line treat-
ment such as trifluridine/tipiracil and regorafenib (Grothey 
et al. 2013; Kubicka et al. 2013; Van Cutsem et al. 2018). 
For maintenance strategies following induction treatment, a 
combination of fluoropyrimidine and bevacizumab is usually 
recommended (Goey et al. 2017; Hegewisch-Becker et al. 
2015; Van Cutsem et al. 2016).
Unlike anti-EGFR treatment, predictive biomarkers for 
the use of cytotoxic and anti angiogenic agents are still miss-
ing. A comprehensive efficacy analysis of these treatment 
strategies in RAS MUT tumors is currently not available.
We, therefore, performed a systematic review and meta-
analysis of randomized controlled phase III trials with EMA/
FDA approved cytotoxic and anti angiogenic agents to evalu-
ate efficacy of the addition of chemotherapeutics and anti 
angiogenic agents when distinguished for RAS status, treat-
ment line and investigated agents.
Methods
Trial identification
Our search strategy included trial identification by system-
atic literature review using the following terms: “metastatic 
colorectal cancer”, “randomized”, “phase III”, “NOT phase 
II”, “NOT meta”, “NOT pooled”. First search was performed 
in February 2019 and last search in November 2019. Only 
trials with available molecular subgroup analysis regard-
ing (K)RAS status (KRAS exon 2–4, NRAS exon 2–4) were 
included. Hence, we included randomized controlled phase 
III trials with available subgroup data for (K)RAS status 
in mCRC evaluating the addition of chemotherapeutic or 
anti angiogenic treatment to a randomised control arm with 
FDA/EMA approved agents. As treatment efficacy should be 
evaluated according to (K)RAS status, trials with anti-EGFR 
treatment requiring (K)RAS wildtype status (cetuximab, pan-
itumumab) were excluded. Patients with BRAF mutations 
were excluded from this analysis if indicated.
Following trials were identified in Pubmed, EMBASE, 
Web Of Science and the Cochrane Central Register of 
Controlled Trials (CENTRAL): TRIBE (Cremolini et al. 
2015), AVG2107g (Hurwitz et al. 2009), FOCUS (Rich-
man et al. 2009), ML22011 (Modest et al. 2018), AGITG 
MAX (Price et al. 2015), ML18147 (Kubicka et al. 2013), 
RAISE (Obermannova et al. 2016), VELOUR (Wirapati 
et al. 2017), CORRECT (Grothey et al. 2013), CONCUR 
(Li et al. 2015), RECOURSE (Van Cutsem et al. 2018), 
AIOKRK0207 (Hegewisch-Becker et al. 2015), CAIRO3 
(Goey et al. 2017), PRODIGE 9 (Aparicio et al. 2018). Data 
were based on publications and/or poster presentations at 
congress meetings.
Trials
TRIBE and ML22011 investigated chemotherapeutic (de-)
escalation strategies on bevacizumab based treatment arms 
in previously untreated mCRC. The MRC FOCUS trial 
compared 5-fluorouracil monotherapy to the combination 
regimes irinotecan/5-fluorouracil (IrFU) and oxaliplatin/5-
fluorouracil (OxFU) as first-line therapy of mCRC. In 
AVG2107g and AGITG MAX, bevacizumab was used 
additionally to chemotherapy in untreated mCRC. All 
second-line trials (ML18147, RAISE, VELOUR) inves-
tigated the role of additional anti angiogenic agents to 
chemotherapy in previously treated patients with mCRC. 
CORRECT and CONCUR compared regorafenib vs. pla-
cebo treatment in mCRC. The RECOURSE trial compared 
single-agent chemotherapy with TAS102 to best support-
ive care. In maintenance, most trials investigated treat-
ment with angiogenic inhibition compared to no treatment 
(AIOKRK0207: bevacizumab ± fluoropyrimidine vs. no 
treatment; CAIRO3: capecitabine + bevacizumab; PROD-
IGE 9: bevacizumab).
Data items, data collection process and summary 
measures
Retrospective data (hazard ratio with confidence interval) 
regarding overall survival (OS) and progression-free sur-
vival (PFS) were collected to compare outcome of chemo-
therapeutic and non-chemotherapeutic treatment addition 
strategies by (K)RAS status in patients with previously 
untreated and treated mCRC and by treatment lines at 
trial level. Control arms were used as reference, meaning 
that hazard ratios smaller than 1 indicated benefit of the 
addition of the respective drug to the treatment protocol.
Risk of bias in individual studies
To ascertain the validity of eligible randomized trials, 
two authors (AS, DPM) determined independently the 
adequacy of trials regarding phase of trial, presence of 
molecular subgroup analysis and strategies of additional 
treatment.
Risk of bias across studies
Primary tumor sidedness, microsatellite instability and 
type of cytotoxic treatment (FOLFIRI or FOLFOX) were 
not considered in this analysis and might have affected the 
cumulative evidence.
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Fig. 1  Workflow of trial identification process; ASCO American Society of Clinical Oncology, ESMO European Society of Medical Oncology
Planned methods of analysis
Standard error estimates were deduced from the 95% 
confidence intervals. Meta-analyses and meta-regression 
analyses based on the log-hazard rate ratios were per-
formed. Random effect meta-regression models were fit-
ted for all trials, for each treatment line (first, second, 
later and maintenance lines) and treatment addition 
(chemotherapeutic vs. anti angiogenic therapy). Interac-
tion effect of RAS mutation type (RAS WT vs. RAS MUT 
tumors) with treatment addition was assessed. Hetero-
geneity explained by mutation was assessed by a Wald 
chi-square test. Residual heterogeneity was determined 
by computing the Cochran’s Q test (chi-square test) and 
the I2 statistic with its 95% confidence interval. In case of 
three-armed trials, correlation of 0.5 was added to treat-
ment effects to integrate repeated comparisons of the 
control group to different experimental treatment arms 
into results. Data analysis was structured to resolve com-
plexity of different result layers. In a first step, benefit 
of therapeutic addition vs. control was investigated for 
all patients regardless of therapy strategy or molecular 
subgroups. Subsequent analyses across all treatment 
lines were performed separately for RAS WT patients 
and for RAS MUT patients, and then for RAS WT vs. 
MUT patients, respectively. Within the molecular sub-
groups, we first compared efficacy of therapeutic addition 
vs. control regardless of substance classes. Then, benefit 
of chemotherapeutic and anti angiogenic strategies were 
analyzed in detail. Finally, each treatment line including 
maintenance was stratified by RAS WT, RAS MUT and 
RAS WT vs. MUT and analyzed for treatment efficacy. 
Weight of the trials was respected by number of trial 
patients. All tests were two-sided and the significance 
level was set to 0.05. The analyses were performed using 
R 3.6.1, particularly packages forestplot and metafor.




Search terms identified 114 phase III trials in total, of 
which 60 trials had to be excluded due to anti EGFR treat-
ment (22 trials), testing of substances not approved by 
FDA/EMA for treatment of metastatic colorectal cancer 
(22 trials) and trial designs which did not compare an 
additional anti-neoplastic drug to standard treatment (16 
trials). Of these remaining trials, 40 trials did not provide 
molecular subgroup analyses for (K)RAS status. (Fig. 1).
Patients
Fourteen trials comprising 10,748 patients were included 
into the analysis. 6 810 patients (63.3%) were evaluated 
according to molecular status. (Table 1) Detailed outcome 
results for each trial in each treatment line according to 
RAS status were presented in supplementary data. (Online 
resources 1–4).
Effect of additional treatment agent (chemotherapy 
and/or anti angiogenic agent)
Across all trials the benefit in overall survival (OS) (HR 0.83 
(95% CI 0.78–0.89), p < 0.0001, p for heterogeneity = 0.25) 
and PFS (HR: 0.60 (95% CI 0.54–0.67), p < 0.0001, p for 
heterogeneity < 0.0001) was significant.
Efficacy analysis in RAS WT vs. MUT tumors across all 
treatment lines
The benefit in OS with the addition of chemotherapeutic 
and/or anti angiogenic agents was significantly greater in 
Table 1  Trial characteristics of the analyzed randomized controlled trials
RAS rat sarcoma, FOLFIRI 5-fluorouracil/folinic acid/irinotecan, FOLFOXIRI 5-fluorouracil/folinic acid/oxaliplatin/irinotecan, IFL irinotecan/5-
fluorouracil/folinic acid, VEGF vascular endothelial growth factor, 5-FU 5-fluorouracil, IrFU irinotecan/5-fluorouracil, OxFU oxaliplatin/5-fluo-
rouracil, FP fluoropyrimidine, TAS102 trifluridin/tipiracil, EGFR epidermal growth factor receptor, ctDNA circulating tumor DNA
Trial name Trial characteristics
Phase Treatment 
line















Chemotherapy 508 391 93 236
AVG2107g III First line IFL IFL + Bevacizumab Anti angiogenic 813 230 152 78
FOCUS III First line 5-FU IrFU; OxFU Chemotherapy 2 135 711 389 300
ML22011 III First line FP + Bevaci-
zumab + Iri-
notecan
FP + Bevacizumab fol-
lowed by Irinotecan
Chemotherapy 421 374 158 194
AGITG-MAX III First line Capecitabine Capecitabine + Bevaci-
zumab(+ Mitomycin)
Anti angiogenic 471 280 171 109
ML18147 III Second line Chemotherapy Chemotherapy + Beva-
cizumab
Anti angiogenic 820 616 316 300
RAISE III Second line FOLFIRI FOLFIRI + Ramu-
cirumab
Anti angiogenic 1 076 1 072 542 530
VELOUR III Second line FOLFIRI FOLFIRI + Aflibercept Anti angiogenic 1 226 482 218 264
CORRECT III Later line Placebo Regorafenib Anti angiogenic 753 729 299 430
CONCUR III Later line Placebo Regorafenib Anti angiogenic 204 143 79 64




Chemotherapy 800 800 393 407
AIOKRK0207 III Maintenance No treatment Bevacizumab Anti angiogenic 472 335 141 172
CAIRO3 III Maintenance No treatment Capecitabine + Bevaci-
zumab
Chemotherapy 558 420 140 240
PRODIGE 9 III Maintenance No treatment Bevacizumab Anti angiogenic 491 375 202 173
Fig. 2  a Forest plot of overall treatment effect of chemotherapeutic 
escalation regarding overall survival for patients with RAS wildtype 
(WT) and mutated (MUT) tumors b Forest plot of overall treatment 
effect of escalation by anti angiogenic escalation regarding overall 
survival for patients with RAS wildtype (WT) and (MUT) tumors. 
OS overall survival, HR hazard ratio, 95% CI 95% confidence inter-
val, RE random effects model. FOCUS upfront IrFU/OxFU vs. FU. 
FOCUS 5-FU: sequential 5-FU then IrFU/OxFU vs. FU
◂
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RAS WT tumors as compared to RAS MUT tumors when all 
studies were analysed together (p for interaction = 0.003). In 
detail, the effect of the addition of a chemotherapeutic agent 
was less pronounced in patients with RAS MUT mCRC 
(WT: HR = 0.74, 95%CI 0.64–0.87; MUT: HR = 0.89, 95% 
CI 0.78–1.02), p for interaction = 0.07) and the addition of 
anti angiogenic treatment was significantly less efficient 
in RAS MUT compared to WT tumors. Interaction of anti 
angiogenic treatment and RAS status was significant (WT: 
HR = 0.78, 95% CI 0.70–0.87; MUT: HR = 0.91, 95%CI 
0.82–1.01; p for interaction = 0.039).
Regarding PFS, the effect of addition of chemotherapeu-
tic and/or anti angiogenic agents was comparable in patients 
with RAS WT and MUT tumors.. However, heterogeneity 
was significant when analysing all trials and the subsets 
of additional chemotherapeutic or anti angiogenic agents 
(p < 0.0001).]. (Figs. 2, 3, Table 2).
Efficacy according to RAS WT or MUT tumors for each 
treatment line
OS was improved regardless of treatment line in RAS WT 
patients. In patients with RAS MUT mCRC, the relative 
improvement of additional treatments was greater in first 
and later-line treatment, while patients in second-line (p for 
interaction = 0.07) did not benefit from additional therapy. 
(Table 3) PFS was improved with the addition of agents in 
all treatment lines.
Maintenance options did not improve OS, but PFS with a 
trend towards higher efficacy in patients with RAS WT com-
pared to MUT tumors (p for interaction = 0.066) (Table 3).
Discussion
Our analysis was motivated by the limited evidence regard-
ing the benefit of adding further treatment to standards (con-
trol arms) in RAS MUT mCRC. One prior meta-analysis 
focussed on the benefit of the addition of bevacizumab to 
first-line treatment and found significantly prolonged PFS 
but not OS in currently used treatment regimen containing 
infusional 5-fluoruracil and irinotecan. However, molecular 
subgroups were not analysed. (Baraniskin et al. 2019) There-
fore, we analysed data from fourteen randomized controlled 
phase III trials with available molecular subgroup data for 
RAS testing in mCRC across several treatment lines.
Fig. 3  a Forest plot of overall treatment effect of chemotherapeutic 
escalation regarding progression free survival for patients with RAS 
wildtype (WT) and mutated (MUT) tumors b Forest plot of overall 
treatment effect of escalation by anti angiogenic escalation regard-
ing progression free survival for patients with RAS wildtype (WT) 
and mutated (MUT) tumors. PFS progression-free survival, HR haz-
ard ratio, 95% CI 95% confidence interval, RE random effects model. 
FOCUS: upfront IrFU/OxFU vs. FU. FOCUS 5-FU: sequential 5-FU 
then IrFU/OxFU vs. FU
◂
Table 2  Efficacy of escalation vs. non-escalation and escalation strategies for OS and PFS (adjusted for trial effect)
RAS rat sarcoma, WT wildtype, MUT mutated, OS overall survival, PFS progression free survival, log HR natural logarithm of hazard ratio, 
VEGF vascular endothelial growth factor
Parameter Therapeutic escalation vs. non-
escalation
Therapeutic escalation strategy
All escalation strategies Chemotherapy Anti angiogenic
RAS WT RAS MUT RAS WT RAS MUT RAS WT RAS MUT
OS












 log(HR) − 0.298 − 0.12 − 0.29 − 0.11 − 0.25 − 0.095
 log(HRMUT)—log(HRWT) 0.178 0.183 0.157
 p value for interaction 0.003 0.07 0.039
 p value for heterogenity 0.93 0.25 0.66
PFS












 log(HR) − 0.597 − 0.487 − 0.63 − 0.48 − 0.54 − 0.443
 log(HRMUT)—log(HRWT) 0.111 0.142 0.093
 p value for interaction 0.093 0.39 0.56
 p value for residual hetero-
genity
0.029  < 0.0001  < 0.0001
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Mutations in KRAS and NRAS genes constitutively acti-
vate the RAS G protein with a high oncogenic potential in 
the MAPK signaling pathway. (Benvenuti et al. 2007) Thus, 
RAS mutations were often associated with worse prognosis 
of mCRC—both due to different biology and due to lack of 
anti-EGFR targeted therapy. (Andreyev et al. 2001, 1998; 
Barault et al. 2008; Cremolini et al. 2015; Hegewisch-
Becker et al. 2018; Modest et al. 2016; Richman et al. 
2009).
Generally, the addition of chemotherapeutic and/or anti 
angiogenic agents demonstrated a significant benefit in 
patients RAS WT and MUT tumors in our meta analysis in 
terms of OS and PFS. However, in patients with RAS MUT 
tumors the benefit in OS with the addition of a new agent 
across all trials and treatment lines was a modest relative risk 
reduction for death of 12%. Although statistically signifi-
cant, it might be argued if 12% can be regarded as clinically 
meaningful improvement. Overall, the addition of agents to 
the comparators was significantly more effective in patients 
with RAS WT tumors when compared to RAS MUT tumors 
in OS and PFS (see Table 2). This finding may suggest that 
RAS WT mCRC represents a more treatment sensitive entity 
in as compared to RAS MUT mCRC independently from 
anti-EGFR antibody therapy.
When studies investigating chemotherapeutic agents were 
analysed separately, a trend towards limited efficacy was 
observed in RAS MUT tumors for OS, but not for PFS. The 
relative risk reduction in RAS MUT tumors in this respective 
setting was only 11% for OS compared to 26% in patients 
with RAS WT mCRC. Importantly, OS benefit from anti 
angiogenic treatment was significantly smaller in patients 
with RAS MUT tumors as compared to RAS WT tumors 
(see Table 2). These results overlap with our findings of less 
meaningful benefit in second-line treatment, as included sec-
ond-line trials investigated anti angiogenic treatment only. 
Overactivation of the MAPK signalling pathway was shown 
to stimulate angiogenesis VEGF-independently and might 
be a reason for low efficacy of anti angiogenic treatment in 
patients with RAS MUT tumors. (Mehta and Besner 2007).
With a detailed view on different treatment lines, later-
line treatment (as compared to control) improved OS to a 
greater extent in patients with RAS WT compared to patients 
with RAS MUT tumors. Although a certain benefit of later-
line therapy was also observed RAS MUT mCRC, the hazard 
Table 3  Efficacy of therapeutic escalation in each treatment line in RAS WT vs. mut tumors
RAS rat sarcoma, WT wildtype, MUT mutated, OS overall survival, PFS progression free survival, log HR natural logarithm of hazard ratio
Parameter Treatment lines
First line Second line Later line Maintenance
RAS WT RAS MUT RAS WT RAS MUT RAS WT RAS MUT RAS WT RAS MUT
OS


























 log(HR) − 0.19 − 0.13 − 0.28 − 0.096 − 0.50 − 0.20 − 0.12 0.03
 log(HRMUT)—
log(HRWT)
0.052 0.18 0.30 0.155
 p value for 
interaction
0.65 0.072 0.018 0.28
 p value for 
heterogenity
0.57 0.85 0.88 0.75
PFS


























 log(HR) − 0.45 − 0.33 − 0.36 − 0.242 − 0.76 − 0.94 − 0.66 − 0.42
 log(HRMUT)—
log(HRWT)
0.126 0.12 0.18 0.249
 p value for 
interaction
0.22 0.24 0.57 0.066
 p value for 
residual het-
erogenity
0.08 0.38 0.01  < 0.0001
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ratio for OS was only 0.81 (see Table 3). This limited effi-
cacy in this treatment setting needs to be considered care-
fully in the context of short observation time (absolute ben-
efit is very moderate) and resulting adverse effects and their 
impact on quality of life in end-stage cancer patients.
Concerning maintenance therapy, our meta-analysis 
included only trials that compared bevacizumab or capecit-
abine plus bevacizumab to best supportive care (BSC). 
(Aparicio et al. 2018; Goey et al. 2017; Hegewisch-Becker 
et al. 2015) A significant effect on overall survival was 
seen in neither RAS WT nor RAS MUT patients, while PFS 
trended to be improved in RAS WT mCRC. When strati-
fied by substances, addition of anti angiogenic therapy 
alone did not improve outcome in the maintenance setting, 
while the combination of capecitabine and bevacizumab 
improved OS in patients with RAS wildtype tumors. These 
results might again strengthen the hypothesis of limited 
benefit of anti angiogenic therapy in patients with RAS 
MUT mCRC. Therefore, our findings raise the question 
if maintenance strategies (instead of treatment holidays) 
should be promoted in patients with RAS MUT tumors. 
Compared to active therapy, careful observation may 
provide a more quality of life friendly approach without 
significant impairment of outcome in patients with RAS 
MUT mCRC.
With 6 810 patients, our meta- analysis represents 
the one of the largest analyses in this setting so far and 
only randomized trials investigating FDA approved drugs 
were included. However, several limitations need to be 
mentioned. As no individual patient data were available, 
published hazard ratios and confidence intervals had to 
be obtained from data extraction. Additionally, two trials 
contained old treatment regimen (IFL and IrFU/OxFU, 
respectively) that are not recommended anymore (Hur-
witz et  al. 2009; Richman et  al. 2009). Our treatment 
subgroups contained more anti angiogenic-based studies 
than chemotherapy investigating trials. In particular, data 
for studies with chemotherapeutic agents beyond first-line 
therapy are rare (only one further line trial) (Van Cut-
sem et al. 2018). This clear relation of treatment lines 
and substance classes might have biased our observation. 
In AIOKRK0207, outcome was distinguished between 
between double wildtype mutational status and any muta-
tion only. Therefore, patients with BRAF MUT tumors 
might have biased AIOKRK0207 results in our analysis, 
although the number should be limited. As most of our 
investigated trials did not distinguish for primary tumor 
side and microsatellite (in)stability, we were not able to 
conduct side-related subgroup analyses. Furthermore, 
potential treatment interaction might have occurred, since 
irinotecan and oxaliplatin were used for cytotoxic treat-
ment. Lastly, significant heterogeneity was observed for 
PFS evaluation in some sub-analyses.
Summary
In summary, our meta-analyses suggests that the addition 
of chemotherapeutic and/or anti angiogenic agents opti-
mizes outcome in RAS WT, but not necessarily in RAS 
MUT mCRC. Treatment efficacy in RAS MUT compared 
to WT mCRC was significantly less evident with advancing 
treatment lines. Furthermore, in this analysis, maintenance 
options improved neither OS nor PFS in patients with RAS 
MUT tumors. Although anti angiogenic therapy is available 
irrespective of RAS status, our overall analysis demonstrates 
meaningful efficacy predominantly in RAS wildtype mCRC.
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